ADMA Biologics
ADMA
52 hedge funds and large institutions have $58M invested in ADMA Biologics in 2018 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 12 closing their positions.
0% more call options, than puts
Call options by funds: $2K | Put options by funds: $2K
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
4.22% less ownership
Funds ownership: 57.5% → 53.28% (-4.2%)
10% less funds holding
Funds holding: 58 → 52 (-6)
37% less capital inflows, than outflows
Capital inflows: $5.43M | Capital outflows: $8.6M
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$657K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$312K |
| 4 |
DG
Delek Group
Herzliya,
Israel
|
+$297K |
| 5 |
CCM
Consonance Capital Management
New York
|
+$243K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$2.65M |
| 2 |
BC
Broadfin Capital
New York
|
-$1.18M |
| 3 |
Renaissance Technologies
New York
|
-$1.17M |
| 4 |
JP Morgan Chase
New York
|
-$986K |
| 5 |
KC
Kepos Capital
New York
|
-$664K |
ADMA Hedge Fund Activity: Q4 2018 in Review
52 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q4 2018, worth a combined $58M — down 65% from $165M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ADMA and 7 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 17 added.
The largest buyer was UBS Group, adding an estimated $1.7M. The largest seller was Pura Vida Investments, cutting an estimated $2.65M.
- 52 institutional investors held ADMA Biologics (ADMA) as of Q4 2018, down from 58 in Q3 2018.
- Funds reported $58M of ADMA Biologics stock for Q4 2018, down 65% quarter-over-quarter.
- 7 funds opened new ADMA Biologics positions in Q4 2018 and 12 closed out, a net change of -5 holders.
- The largest ADMA Biologics buyer in Q4 2018 was UBS Group, an estimated $1.7M added.
- The largest ADMA Biologics seller in Q4 2018 was Pura Vida Investments, an estimated $2.65M sold.
Based on aggregated 13F filings for Q4 2018.